IBD patients exhibit depleted beneficial bacteria (e.g., butyrate-producing Clostridium ), increased pathogenic bacteria, and reduced SCFAs
The FDA's concerns cite peptide manufacturing risks: incompletely characterised active ingredient, peptide fragments, degradation products, and impurities that the immune system may recognise as foreign
Using the wrong ICD-10 with the right CPT triggers CO-11 denials
Selective metabolic activity: Research has documented that the C-terminal GH fragment exhibits activity in lipid metabolism pathways in laboratory models, particularly in relation to adipocyte biology and lipolytic enzyme activity, without the full growth-promoting and insulin-antagonistic effects of the complete GH molecule
In colitis models, the peptide significantly reduced inflammatory markers and macroscopic damage signs